Alison Bateman-House

Alison Bateman-House, MPH, PhD

Assistant Professor, Department of Population Health

Keywords
Clinical trials, Compassionate use, Access to investigational medical products
Summary

I am an ethicist, a public health professional, and a medical historian. My research is primarily focused on ethics and policy issues concerning access to investigational medical products, both inside and outside of clinical trials. One particular area of interest is in the equity of access: who gets access to what, how?
In recent years, my colleagues and I have become interested in several areas of active inquiry: 1) can useful efficacy data be obtained from non-trial uses of unapproved medical products; 2) how to most ethically and pragmatically advance the new field of individualized therapeutics; 3) the ethics of pediatric gene therapy trials; and 4) what amount of and quality of data is needed to make clinical & regulatory decisions.
I am also interested in and conducted research on the history, ethics, & public policy of mandatory helmet laws.

Phone

646-359-9318

Fax

646-501-2830

Academic office

227 East 30th Street

7th Floor, #723

New York, NY 10016

Is this your profile?
Edit profile

Positions

Assistant Professor, Department of Population Health at NYU Grossman School of Medicine

Graduate Education

PhD from Columbia University

MPH from Columbia University

Postdoctoral Training

NYU Grossman School of Medicine, Division of Medical Ethics

Right-to-Try Laws: Hope, Hype, and Unintended Consequences

Bateman-House, Alison; Kimberly, Laura; Redman, Barbara; Dubler, Nancy; Caplan, Arthur

Annals of internal medicine. 2015 Nov 17; 163(10):796-7

Should patients in need be given access to experimental drugs?

Caplan, Arthur L; Bateman-House, Alison

Expert opinion on pharmacotherapy. 2015 Jun; 16(9):1275-9

Patient-centered long-term follow-up for gene therapies aligns with ethics and science

Chapman, Carolyn Riley; Cripe, Timothy P; Bateman-House, Alison S

Molecular therapy : the journal of the American Society of Gene Therapy. 2025 May 14;

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap

Jonker, Anneliene H; Tataru, Elena-Alexandra; Graessner, Holm; Dimmock, David; Jaffe, Adam; Baynam, Gareth; Davies, James; Mitkus, Shruti; Iliach, Oxana; Horgan, Rich; Augustine, Erika F; Bateman-House, Alison; Pasmooij, Anna Maria Gerdina; Yu, Tim; Synofzik, Matthis; Douville, Julie; Lapteva, Larissa; Brooks, Philip John; O'Connor, Daniel; Aartsma-Rus, Annemieke; ,

Nature reviews. Drug discovery. 2025 Jan; 24(1):40-56

From roadmap to a sustainable end-to-end individualized therapy pathway

Jonker, Anneliene H; Tataru, Elena-Alexandra; Dimmock, David P; Bateman-House, Alison; Graessner, Holm; Baynam, Gareth; Augustine, Erika F; Jaffe, Adam; Pasmooij, Anna M G; Iliach, Oxana; Horgan, Richard; Davies, James; Mitkus, Shruti; Lapteva, Larissa; Synofzik, Matthis; Yu, Timothy W; O'Connor, Daniel; Aartsma-Rus, Annemieke

Therapeutic advances in rare disease. 2025 May; 6:26330040251339204

Lived Experience of Patients and Caregivers in Rare Genetic Neurological Gene Therapy Clinical Trials in Children

Bateman-House, Alison; Cowley, Kirsten; Fernandez, Vivian; Gilmor, Michelle; Hunt, Cara; Nevoret, Marie-Laure; Ward, Erin; Shah, Lesha D; Smith, Jared B

Pediatric neurology. 2024 Nov 09; 163:46-49

ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies

Gardner, Rebecca A; White, Claire; Elsallab, Magdi; Farnia, Stephanie; Fraint, Ellen; Grilley, Bambi; Bateman-House, Alison; Grupp, Stephan A; Kenderian, Saad; Locke, Frederick L; Nikiforow, Sarah; Oluwole, Olalekan O; Rouce, Rayne H; Spiegel, Jay; Shah, Nirali N; Sharma, Akshay; Komanduri, Krishna; Gill, Saar

Transplantation & cellular therapy. 2024 Aug; 30(8):776-787

Somatic Gene Therapy: Ethics and Access

Bateman-House, Alison

Annual review of genomics & human genetics. 2024 Aug; 25(1):421-438

See All Publications (55)